医生对心力衰竭处方药物的看法:一个全面的审查
Swetha Vasudevan1, Archana Thayaparan2, Lung En Teng2
1Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia, svas0001@student.monash.edu.
Cardiology
|May 27, 2024
概括
医生在为心力衰竭 (HF) 开处方指南导向医学疗法 (GDMT) 时,面临诸如副作用的担忧和不清楚的角色等障碍. 解决这些推动因素可以改善GDMT的实施,以获得更好的患者结果.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 医疗保健服务研究 医疗服务研究
背景情况:
- 在心力衰竭 (HF) 中,指南导向医学疗法 (GDMT) 已证明有效性,但临床采用速度缓慢.
- 糖共运输体2抑制剂代表了一种新的,有益的治疗HF.
- 了解医生的观点对于弥合HF指南和临床实践之间的差距至关重要.
研究的目的:
- 探索医生在心力衰竭 (HF) 中处方GDMT的观点.
- 确定影响采用新型HF疗法的障碍和推动因素.
- 在临床实践中改进GDMT实施的策略.
主要方法:
- 根据PRISMA指南进行了范围审查.
- 在2024年4月的EMBASE,Medline和PubMed数据库中进行了搜索.
- 包括评估医生对HF药物处方的观点的定性研究,并使用专题合成进行分析.
主要成果:
- 从708项初步搜索中,包括了23项研究.
- 关键障碍包括对副作用的担忧,不清楚的跨专业角色,患者的并发症以及不愿改变稳定的患者治疗方案.
- 启用因素包括对疗效的认识,同行影响和多媒体信息传播;根据处方组和随着时间的推移,人们的看法各不相同.
结论:
- 医生认识到在高频率患者处方GDMT的常见障碍和促进因素.
- 尽管处方组和时间之间存在差异,这些因素仍然存在.
- 针对已识别的障碍和促进因素,可以加强GDMT在心力衰竭护理中的实施.
相关概念视频
01:22Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
01:22Heart Failure Drugs: Diuretics
363
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
363
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:26Heart Failure Drugs: Inotropic Agents
570
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
570
01:15Drug Abuse and Addiction: Pharmacological Phenomena
465
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
465